MBX Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by MBX Biosciences, Inc. on June 4, 2026. The filing details the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters.
Material Changes and Voting Results
As of the record date (April 10, 2026), there were 47,570,485 shares of common stock outstanding. Stockholders approved the following proposals:
- Proposal 1 (Election of Directors): Two Class II director nominees were elected to serve until the 2029 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Breakdown
| Nominee / Proposal | For | Against / Withhold | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Patrick J. Heron (Director) | 35,007,623 | 4,579,129 | - | 4,130,833 |
| Edward T. Mathers (Director) | 31,983,223 | 7,603,529 | - | 4,130,833 |
| Ratify Ernst & Young LLP | 43,713,693 | 1,946 | 1,946 | - |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Board composition with Patrick J. Heron and Edward T. Mathers serving Class II terms through 2029.
- Verification of the significant number of broker non-votes (4,130,833) on the director elections, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirmation that Ernst & Young LLP remains the independent auditor for the 2026 fiscal year.